ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 14, 2018 00:50 JST
Source:
Jacobson Pharma Corporation Limited
Jacobson Pharma Updates on TAILORx Study
Landmark TAILORx Results, Published in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving
HONG KONG, Jun 13, 2018 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), the Hong Kong and Macau exclusive distributor of Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests, is pleased to share that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25. The long-awaited results of the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), provided definitive evidence that the Oncotype DX Breast Recurrence Score test identified 70 per cent of early-stage breast cancer patients who received no benefit from chemotherapy, and can be effectively treated with endocrine therapy alone. Additionally, the trial established that chemotherapy may provide life-saving benefit to 30 per cent of patients.
The TAILORx results were published on June 3rd in The New England Journal of Medicine in conjunction with a presentation during the Plenary Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, United States.
The Oncotype DX gene expression tests carried out by Genomic Health have been used to guide treatment decisions for more than 900,000 cancer patients in more than 90 countries. The Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment.
Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "Breast cancer is one of the most common types of cancerous disease with about 4,000 new cases found in Hong Kong, as well as about 270,000 new cases in China. . Jacobson has been the exclusive distributor of Genomic Health in Hong Kong and Macau for 10 years. We are confident that with our close collaboration with Genomic Health and our in-depth experiences in the relevant markets, we are well positioned to continue expanding business opportunities emerging in this arena."
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012. The Group's proprietary medicines, notably being Po Chai Pills, Tong Tai Chung Woodlok Oil, Ho Chai Kung Tji Thung San, Contractubex Scar Gel Doan's Ointment, Flying Eagle Wood Lok Medicated Oil, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognized by the market. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email:
vicky.lee@sprg.com.hk
Stephanie Liu Tel: (852) 2864 4852 Email:
stephanie.liu@sprg.com.hk
Queenie Chan Tel: (852) 2864 4851 Email:
queenie.chan@sprg.com.hk
Fax: (852) 2527 1196
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Nov 01, 2024 13:56 JST
All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024
Nov 01, 2024 12:43 JST
Fujitsu's groundbreaking computing technology for accelerating scientific computing wins Japan Patent Office Commissioner's Award
Nov 01, 2024 12:24 JST
Fujitsu and AMD to begin strategic partnership to develop more sustainable computing infrastructure intended to accelerate open-source AI initiatives
Nov 01, 2024 10:45 JST
Mazda Launches Redesigned Corporate Website
Oct 31, 2024 17:06 JST
NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents
Oct 31, 2024 16:34 JST
All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024
Oct 31, 2024 16:08 JST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 13:56 JST
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 31, 2024 11:33 JST
Mazda Production and Sales Results for September 2024 and for April through September 2024
Oct 30, 2024 17:09 JST
Suzuki and Toyota to Deepen Collaboration in the Field of Electrified Vehicles
Oct 30, 2024 16:14 JST
Fujitsu and Morinaga Milk Industry jointly develop a simulation system for raw material price fluctuations, speeding up decision-making
Oct 30, 2024 13:43 JST
DOCOMO to Participate in Virtual Expo at Expo 2025 Osaka, Kansai, Japan
Oct 30, 2024 12:47 JST
ULVAC Launches Technology Center PYEONGTAEK for Next-Gen Semiconductor Manufacturing Equipment in South Korea
Oct 30, 2024 11:00 JST
Fujitsu and Linius partner to unlock the power of video worldwide
Oct 29, 2024 19:53 JST
DENSO and U.S. Startup Quadric Sign Development License Agreement for AI Semiconductor (NPU)
Oct 29, 2024 13:03 JST
Toyota Motor Corporation and Hyundai Motor Company Co-host Motorsport Event to Share the Excitement of Racing
Oct 28, 2024 20:53 JST
NEC launches new end to end private 5G solution with Cisco
Oct 28, 2024 17:05 JST
Mitsubishi Power Receives Order for Facility Retrofit at the Darajat Geothermal Power Plant in Indonesia
Oct 28, 2024 15:35 JST
GS Holdings to Acquire Integrated Beverage Solutions Group, Octopus Distribution Networks, for S$11.8 Million; Expected to Yield Significant Opportunities and Additional Financial Benefits
Oct 28, 2024 09:00 JST
More Latest Release >>
Related Release
Jacobson Pharma Announces FY2023 Interim Results
November 25 2022 21:21 JST
Jacobson Pharma Announces FY2022 Annual Results
June 29 2022 23:20 JST
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 15 2022 19:56 JST
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
March 14 2022 19:58 JST
Jacobson Pharma Announces FY2022 Interim Results
November 26 2021 19:39 JST
Jacobson Pharma Announces FY2021 Annual Results
June 29 2021 23:19 JST
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
February 05 2021 16:28 JST
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
January 25 2021 17:20 JST
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
January 15 2021 23:25 JST
Jacobson Pharma Announces FY2021 Interim Results
November 27 2020 20:10 JST
More Press release >>